Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0I0SY
|
||||
| Former ID |
DIB001164
|
||||
| Drug Name |
MEDI-542
|
||||
| Synonyms |
Ephrin a4-targeting monoclonal antibody (cancer), MedImmune
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Solid tumours [ICD9: 140-199, 210-229; ICD10:C00-D48] | Terminated | [1] | ||
| Company |
Medlmmune LLC
|
||||
| Target and Pathway | |||||
| Target(s) | Epha4 tyrosine kinase receptor | Target Info | [2] | ||
| KEGG Pathway | Axon guidance | ||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| Pathway Interaction Database | EphrinA-EPHA pathway | ||||
| EPHA forward signaling | |||||
| Reactome | EPH-Ephrin signaling | ||||
| EPHA-mediated growth cone collapse | |||||
| EPH-ephrin mediated repulsion of cells | |||||
| WikiPathways | Gene regulatory network modelling somitogenesis | ||||
| Spinal Cord Injury | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021498) | ||||
| REF 2 | Product Pipeline Review of MedImmune, LLC in 2012. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.